Holen Sie sich die Stockscreener-App
1.70
1.73%
-0.03
Handel nachbörslich:
1.71
0.01
+0.59%
Schlusskurs vom Vortag:
$1.73
Offen:
$1.79
24-Stunden-Volumen:
101.02K
Relative Volume:
0.17
Marktkapitalisierung:
$133.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-9.57%
1M Leistung:
-10.99%
6M Leistung:
+156.10%
1J Leistung:
+61.90%
1-Tages-Spanne:
$1.68
$1.84
1-Wochen-Bereich:
$1.68
$1.92
52-Wochen-Spanne:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Firmenname
Citius Oncology Inc
Sektor
Telefon
(908) 967-6677
Adresse
11 COMMERCE DRIVE, CRANFORD
Vergleichen Sie CTOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.70 | 144.48M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
143.46 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.80 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.17 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.61 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-11-27 | Eingeleitet | Maxim Group | Buy |
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Why Citius Oncology Inc. stock is recommended by analysts2025 Analyst Calls & Reliable Trade Execution Plans - newser.com
Sector ETF performance correlation with Citius Oncology Inc.Trade Analysis Summary & Short-Term High Return Strategies - newser.com
Real time breakdown of Citius Oncology Inc. stock performanceGDP Growth & Weekly Market Pulse Alerts - newser.com
What to do if you’re stuck in Citius Oncology Inc.Trade Volume Report & High Return Stock Watch Alerts - newser.com
How Citius Oncology Inc. stock benefits from tech adoptionLayoff News & Accurate Intraday Trading Signals - newser.com
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Is Citius Oncology Inc. stock attractive for long term wealth buildingBuy Signal & Fast Moving Stock Watchlists - newser.com
Is Citius Oncology Inc. stock bottoming out2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Is it too late to sell Citius Oncology Inc.July 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Is Citius Oncology Inc. a candidate for recovery playStock Surge & Safe Swing Trade Setup Alerts - newser.com
Heatmap analysis for Citius Oncology Inc. and competitors2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How Citius Oncology Inc. stock performs in stagflationTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
Will a bounce in Citius Oncology Inc. offer an exitMarket Movement Recap & Safe Entry Zone Identification - newser.com
Has Citius Oncology Inc. formed a bullish divergenceVolume Spike & Daily Volume Surge Signals - newser.com
Is it time to cut losses on Citius Oncology Inc.Trade Volume Report & Real-Time Stock Price Movement Reports - newser.com
Citius in talks over Lymphir access in global markets - The Pharma Letter
Citius Oncology expands LYMPHIR access through named patient programs By Investing.com - Investing.com Canada
Citius Sets Up Access to Lymphir in Southern Europe - MarketScreener
Citius Oncology expands LYMPHIR access through named patient programs - Investing.com
Citius Oncology enters exclusive distribution agreement with Integris Pharma S.A. - MarketScreener
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Decline in Short Interest - Defense World
Is a relief rally coming for Citius Oncology Inc. holdersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
Can volume confirm reversal in Citius Oncology Inc.July 2025 Highlights & Low Risk Entry Point Tips - newser.com
Using data tools to time your Citius Oncology Inc. exit2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com
What MACD and RSI say about Citius Oncology Inc.Trade Risk Report & Long-Term Safe Return Strategies - newser.com
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September - MarketBeat
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - Nasdaq
Finanzdaten der Citius Oncology Inc-Aktie (CTOR)
Es liegen keine Finanzdaten für Citius Oncology Inc (CTOR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
2.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):